What is the expensive HIV medication starting with S that was prescribed alongside Truvada (emtricitabine + tenofovir disoproxil fumarate) for post‑exposure prophylaxis, and could it be responsible for my reduced renal function (eGFR 56 mL/min/1.73 m²)?

Identifying Your HIV Medication and Addressing Renal Concerns

The expensive HIV medication starting with "S" that you received alongside Truvada for post-exposure prophylaxis (PEP) is most likely Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine), and yes, both medications contain tenofovir which can contribute to your reduced kidney function (eGFR 56 mL/min/1.73 m²).

Understanding Your Medications

Your PEP regimen likely consisted of:

• Truvada (tenofovir disoproxil fumarate/emtricitabine)
• Stribild or possibly another medication starting with "S" such as:
  • Saquinavir (older protease inhibitor, rarely used now)
  • Sustiva (efavirenz, brand name)

However, Stribild is the most probable candidate given it's a commonly prescribed, expensive single-tablet regimen used for PEP 1, 2.

Critical Renal Function Concern

Your eGFR of 56 mL/min/1.73 m² represents moderate chronic kidney disease (Stage 3a), and tenofovir-containing medications should be discontinued or dose-adjusted at this level 3, 4, 5.

Why This Matters for Your Kidneys

Tenofovir disoproxil fumarate (TDF), the active component in Truvada, causes proximal renal tubular toxicity through concentration-dependent accumulation in kidney tubules 6. The 2014 HIV Medicine Association guidelines explicitly recommend that tenofovir should be discontinued in patients who develop reduced eGFR by >25% from baseline and to a level <60 mL/min/1.73 m² 3.

Key nephrotoxic mechanisms:

• Proximal tubular dysfunction leading to Fanconi syndrome (renal failure, hypophosphatemia, proteinuria, glycosuria) 6
• 1-2% of recipients develop treatment-limiting tubulopathy 4
• Risk increases with ritonavir-boosted protease inhibitors or cobicistat (both block the MRP-2 transporter, increasing tenofovir exposure by 32%) 6

If You Received Stribild

Stribild contains cobicistat, which significantly increases tenofovir exposure and nephrotoxicity risk 4. The 2018 KDIGO guidelines note that cobicistat increases tenofovir exposure and may increase toxicity risk, though it's not as well studied as ritonavir-boosted regimens 4.

Immediate Actions Required

1. Stop Tenofovir-Containing Medications Immediately

With an eGFR of 56 mL/min/1.73 m², you should not continue tenofovir 3, 5, 7. The FDA label for Truvada explicitly states: "TRUVADA should not be administered to patients with estimated creatinine clearance below 30 mL/min" for treatment, and "should not be used if estimated creatinine clearance is less than 60 mL/min" for PrEP 7.

2. Assess for Proximal Tubular Dysfunction

Check for signs of Fanconi syndrome 3:

• Euglycemic glycosuria (glucose in urine without diabetes)
• Hypophosphatemia with increased urinary phosphorus excretion
• New or worsening proteinuria
• Bone pain or muscle weakness (may indicate osteomalacia from proximal tubulopathy) 7

3. Monitor Renal Recovery

After stopping tenofovir:

• Most cases of tenofovir-associated nephrotoxicity improve or resolve with discontinuation 6
• Repeat creatinine and eGFR in 2-4 weeks
• Continue monitoring every 4-12 weeks until stable

4. Identify Contributing Factors

Risk factors that worsen tenofovir nephrotoxicity 4:

• Age ≥40 years (OR 3.79 for developing eGFR <70) 8
• Baseline eGFR <90 mL/min/1.73 m² (OR 9.59) 8
• Diabetes
• Prolonged tenofovir exposure
• Concurrent nephrotoxic drugs (NSAIDs, aminoglycosides) 3, 7
• Low BMI <18.5 kg/m² (OR 71.8 for renal adverse events) 9
• Protein supplements, creatine, anabolic steroids (can falsely elevate creatinine) 10

Alternative PEP/Treatment Options

If you need to continue HIV treatment or PEP, switch to non-tenofovir regimens 4, 5, 4:

Preferred alternatives with eGFR <60 mL/min/1.73 m²:

• Abacavir/lamivudine (does not require dose adjustment) 5
• Tenofovir alafenamide (TAF) if creatinine clearance >30 mL/min (less nephrotoxic than TDF, though long-term safety data limited) 4, 5, 4
• Dolutegravir-based regimens 11, 12

Avoid these with your kidney function 4:

• TDF (tenofovir disoproxil fumarate)
• Atazanavir (linked to interstitial nephritis and rapid eGFR decline)
• Lopinavir/ritonavir (associated with rapid eGFR decline)

Common Pitfalls to Avoid

1. Don't assume creatinine elevation is solely from supplements or muscle mass - While protein supplements and creatine can elevate creatinine 10, your eGFR of 56 requires investigation for true kidney injury
2. Don't continue tenofovir with dose adjustment alone at this eGFR - Guidelines recommend discontinuation, not just dose reduction, when eGFR drops >25% to <60 mL/min/1.73 m² 3
3. Don't ignore subtle signs of tubular dysfunction - Glycosuria, phosphate wasting, and bone pain may precede significant eGFR decline 3, 7

Next Steps

1. Contact your prescribing physician immediately to discuss stopping tenofovir-containing medications
2. Request comprehensive renal workup: urinalysis with protein, glucose, phosphate levels, urine protein-to-creatinine ratio
3. Consider cystatin C testing if creatinine elevation may be confounded by muscle mass or supplements 10
4. If HIV treatment is needed, switch to abacavir-based or TAF-based regimen with appropriate monitoring

Your kidney function decline is likely reversible if tenofovir is stopped promptly 6, but continued use risks progressive renal impairment and potential Fanconi syndrome.